Novartis and BMS Suspend CAR-T Trials Amid Safety Issues

Recent developments have emerged in the pharmaceutical landscape, particularly concerning Novartis and Bristol Myers Squibb (BMS), who have both decided to pause their autoimmune CAR-T trials due to safety concerns. This article highlights these suspensions, significant licensing agreements, and a call for more comprehensive strategies in obesity treatment.

Safety Concerns Lead to Trial Pauses

Novartis has announced the halt of eight autoimmune studies involving its CAR-T therapy, Rap-cel, which targets conditions such as lupus, myasthenia gravis, and multiple sclerosis. The decision follows three reported fatalities linked to immune effector cell-associated hemophagocytic syndrome. Notably, ongoing cancer studies utilizing the same therapy remain unaffected.

Bristol Myers Squibb has similarly paused enrollment in its Zola-cel autoimmune trials. This includes a planned study for systemic sclerosis, prompted by the detection of transient inflammatory events during routine monitoring. The company is currently reviewing the data and aims to resume activities as soon as it is prudent to do so.

Deal Making in the Pharmaceutical Sector

In addition to the trial suspensions, several noteworthy licensing agreements have surfaced this week. Alteogen has entered into a substantial option and license agreement with Novartis, potentially worth up to $3.223 billion. This partnership grants Novartis rights to develop subcutaneous formulations of its biologics by using Alteogen’s innovative ALT-B4 hyaluronidase technology, which can transform intravenous drugs into faster-acting subcutaneous versions.

Another significant partnership involves NewBiologix, which is collaborating with Synastra Biotechnology to create a stable producer cell line for their investigational gene therapy aimed at treating Duchenne muscular dystrophy. This partnership seeks to address manufacturing challenges associated with high-dose viral vector therapies.

Meanwhile, RedHill Biopharma has acquired global rights to Rebyota, a microbiota-based therapy intended to prevent the recurrence of C. difficile infections, as well as U.S. rights to Clenpiq, a bowel preparation product. The acquisition deal is valued at $12 million upfront, accompanied by potential royalties and milestone payments.

The Need for Real-World Insights in Obesity Treatment

Lexi Cogswell and Tom Rotolo emphasize the necessity for a shift in pharmaceutical medical strategies concerning obesity management. They argue that focusing solely on real-world evidence is inadequate; instead, there is a pressing need to derive real-world insights that elucidate the underlying reasons for treatment outcomes and guide future actions.

The authors highlight that conventional methods of data dissemination are falling short as obesity rates continue to rise. They advocate for the development of frameworks that enhance the understanding of patient journeys, support healthcare professionals, and showcase the value of innovations in clinical settings. This approach represents a potential paradigm shift in medical strategy that could significantly impact the field.

Conclusion

The temporary suspension of CAR-T trials by Novartis and Bristol Myers Squibb underscores the complexities and challenges in advancing innovative therapies within the pharmaceutical industry. Alongside notable licensing agreements and a push for enhanced strategies in obesity treatment, these developments reveal the dynamic nature of the biopharmaceutical sector. As companies navigate these challenges, the focus on safety, strategic partnerships, and patient-centered insights will be crucial for future success.

• Key Takeaways:
  • Novartis and BMS halt CAR-T trials due to safety issues.
  • Alteogen and Novartis enter a $3.223 billion licensing deal.
  • NewBiologix partners with Synastra to tackle gene therapy manufacturing challenges.
  • RedHill acquires global rights to microbiota therapy Rebyota.
  • Experts call for real-world insights to enhance obesity treatment strategies.

Read more → www.pharmexec.com